Discover how Alpha-hederin is revolutionizing the treatment of non-small cell lung cancer (NSCLC) by overcoming drug resistance through the reprogramming of multi-miRNAs activity, a breakthrough in the field of nuclear medicine.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Alpha-hederin reprograms multi-miRNAs activity and overcome small extracellular vesicles-mediated paclitaxel resistance in NSCLC.
Chang et al., Front Pharmacol 2024
<!– DOI: 10.3389/fphar.2024.1257941 //–>
https://doi.org/10.3389/fphar.2024.1257941
This study explores the potential of alpha-hederin in overcoming paclitaxel (PTX) resistance in non-small cell lung cancer (NSCLC) through targeting small extracellular vesicles (sEVs). Utilizing the PTX-resistant A549T cell line, the research demonstrates that alpha-hederin impedes the transmission of chemoresistance via sEVs. Key methods included the CCK-8 assay, flow cytometry, transcriptomics, Western blot, and more, to assess the impact on signaling pathways associated with chemoresistance. The results showed that alpha-hederin overcame PTX resistance by affecting sEV secretion, specifically inhibiting unsaturated fatty acid synthesis and the TGFβ/SMAD2 pathway. Additionally, alpha-hederin increased the production and sEV sorting of three microRNAs (miR-21-5p, miR-23a-3p, and miR-125b-5p), which targeted the TGFβ/SMADs signaling in recipient cells, enhancing their sensitivity to PTX. This study highlights alpha-hederin’s potential in reprogramming the tumor microenvironment and sensitizing PTX-resistant NSCLC cells to chemotherapy through sEV-mediated mechanisms.